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Abstract
Gold nanoparticle accumulation in immune cells has commonly been viewed as a side effect for cancer therapeutic delivery;
however, this phenomenon can be utilized for developing gold nanoparticle mediated immunotherapy. Here, we
conjugated a modified CpG oligodeoxynucleotide immune stimulant to gold nanoparticles using a simple and scalable self-
assembled monolayer scheme that enhanced the functionality of CpG in vitro and in vivo. Nanoparticles can attenuate
systemic side effects by enhancing CpG delivery passively to innate effector cells. The use of a triethylene glycol (TEG) spacer
on top of the traditional poly-thymidine spacer increased CpG macrophage stimulatory effects without sacrificing DNA
content on the nanoparticle, which directly correlates to particle uptake. In addition, the immune effects of modified CpG-
AuNPs were altered by the core particle size, with smaller 15 nm AuNPs generating maximum immune response. These TEG
modified CpG-AuNP complexes induced macrophage and dendritic cell tumor infiltration, significantly inhibited tumor
growth, and promoted survival in mice when compared to treatments with free CpG.
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Introduction
Synthetic oligodeoxynucleotides (ODNs) containing the un-
methylated cytosine-phosphate-guanine (CpG) motif are potent
stimulants of the innate immune system. These sequences bind to
Toll-like receptor 9 (TLR9) in the endosome of antigen presenting
cells (APCs), thus promoting the expression of co-stimulatory
molecules, the secretion of inflammatory cytokines, and the
development of CD8+ T cell responses [1,2]. As a result, CpG
ODNs have shown great promise as a monotherapy and as a
vaccine adjuvant for the treatment of cancer [3–5]. Although
many studies have focused on the effects that CpG ODNs have on
B cells and plasmacytoid dendritic cells (pDCs), these sequences
also have important effects on macrophages and myeloid derived
suppressor cells (MDSCs). For instance, the antitumor effects of
CpG immunotherapy in weakly immunogenic tumors are mainly
mediated by macrophages as opposed to T cells [6]. CpG ODNs
can directly inhibit the immunosuppressive functions of MDSCs
and cause them to differentiate into macrophages with antitumor
activity [7]. CpG ODNs can also suppress MDSC activity by
indirectly stimulating pDCs to produce interferon-a (IFNa) which
in turn promotes MDSC differentiation [8]. Thus, targeting these
immune cells in the tumor microenvironment is clinically relevant.
As nanoparticles are naturally cleared by macrophages,
dendritic cells (DCs), and other APCs [9–11], they are excellent
carriers for CpG delivery to innate immune cells. Liposomal
nanoparticle encapsulation methods enhanced the immune
stimulatory effect of CpG and promoted antitumor activity when
combined with ovalbumin immunization [12]. Bourqin and
colleagues also demonstrated that ovalbumin immunization
combined with CpG encapsulating gelatin nanoparticles produced
significantly higher activation of CD8+ T cells than when
combined with free CpG oligos [13]. In addition, the encapsula-
tion of CpG reduced the systemic release of pro-inflammatory
cytokines and attenuated systemic side effects such as lymphoid
follicle destruction and splenomegaly [13]. Similarly, Kwong et al.
found that CpG and anti-CD40 monoclonal antibody encapsu-
lated in liposomes were more effective than free CpG and induced
significantly lower levels of IL-6 and TNFa in the serum [14].
Currently, however, the use of nanocarrier delivered CpG has not
been tested as a monotherapy against cancer. Also, these
encapsulation methods generate particles ranging from
PLOS ONE | www.plosone.org 1 May 2013 | Volume 8 | Issue 5 | e63550
100–200 nm in diameter, far from the optimal 50–60 nm size
range for maximum particle uptake [15].
Gold nanoparticles (AuNPs) can be easily functionalized with
thiol-modified synthetic oligonucleotides to form a self-assembled
monolayer [16], making them useful platforms for the delivery of
CpG ODN. AuNPs are also desirable vehicles because they are
inert, biocompatible, and possess optical properties tunable for
diagnostic and photothermal applications [17], In addition, DNA
strands that are conjugated on AuNPs are more resistant to
nuclease degradation [18]. Most importantly, AuNPs are readily
taken up by immune cells [11,19] and collect in endosomes
[15,20,21], thereby facilitating access to TLR9 within antigen
presenting cells. Given these characteristics, we hypothesize that
CpG-coated AuNPs can enhance delivery of CpG to the target
TLR9 receptor, thus enhancing the therapeutic effect of the
oligonucleotide.
We developed a modified CpG ODN conjugated gold
nanoparticle design to target innate immune cells in vitro and
in vivo in order to mount an anti-tumor immune response. The
design is optimized to maintain DNA content on the particle and
to promote cellular uptake. We show that CpG conjugated AuNPs
significantly enhance macrophage stimulation in vitro and inhibit
tumor growth in vivo when compared to treatments with the
equivalent dose of free CpG. The antitumor effect of the CpG-
AuNP particles is potent and does not require combination
treatment, suggesting that these complexes are clinically applicable
and can be used for CpG monotherapy.
Materials and Methods
Cell Culture
The macrophage cell line J774.A1 (ATCC) was maintained in
Dulbecco’s Modified Eagle Medium (DMEM), supplemented with
10% Fetal Bovine Serum (FBS) and 1% penicillin/streptomycin.
The B16-OVA cell line was kindly provided by Dr. Xiao-Tong
Song (Baylor College of Medicine) [22] and cultured in Dulbecco’s
Modified Eagle Medium (DMEM), supplemented with 10% FBS,
2 mM Glutamax (Invitrogen, Carlsbad, CA), and 0.5 mg/ml
Geneticin (Invitrogen). The cells were maintained at 37uC and 5%
CO2.
Particle Synthesis
Citrate stabilized gold nanoparticles (15 nm, 30 nm, and
80 nm) were purchased from Ted Pella. Modified CpG 1826
designs were purchased from Integrated DNA Technology (IDT).
All reagents were purchased from Sigma Aldrich unless specified
otherwise. All DNA types were uncapped by incubation with
100 mM dithiothreitol in sodium phosphate solution, pH 8.5, and
eluted though illustra NAP-5 columns (GE Healthcare) with
sodium phosphate solution, pH 6.5, after 1 hr incubation at 25uC.
Uncapped CpG sequences (0.5 mM end concentration) were
added to citrate stabilized gold nanoparticles for 24 hrs. The
solution was brought to 1x phosphate buffered saline (PBS) and
0.1% Tween 20 and placed on a nutator for another 24 hrs. The
particles were then collected and washed with PBS through three
centrifugation steps. 15 nm particles were spun at 13,200 g for
20 min, 30 nm particles were spun at 7,000 g for 20 min, and
80 nm particles were spun at 1,000 g for 20 min.
CpG 1826 Sequences
Three different designs were conjugated on gold nanoparticles.
Design 1: 59-HS-C6-TCCATGACGTTCCTGACGTT-39. De-
sign 2: 59-HS-C6-TTTTTTTTTTT-TCCATGACGTTCCT-
GACGTT-39. Design 3 (tmCpG): 59-HS-C6-TTTTTTTTTTT-
(CH2CH2O)3-TCCATGACGTTCCTGACGTT-39.
CpG Content on AuNP Measurements
The particle concentration of 15 nm or 30 nm AuNPs
conjugated with CpG of varying designs were calculated by
comparing the optical density of the solution with that of the
purchased AuNP stock solution. The particles were then incubated
with 1.4 mM mercaptoethanol for 48 hours. After incubation, the
particles were spun at 16,000 g for 10 minutes. Using the
absorbance of the supernatants at 260 nm and the extinction
coefficients of each DNA, as provided by IDT, we calculated the
concentration of DNA in the supernatants. The CpG concentra-
tion and gold nanoparticle concentration ratio gave the number of
DNA per AuNP.
Stimulation with CpG ODN and AuNP CpG Particles
J774.A1 macrophage cells were seeded at 16105 cells/ml in 12
well plates and cultured for 2 days. The cells were then exposed to
their respective treatment conditions in triplicate and incubated
for 24 hours. After incubation, the cell supernatants were collected
and stored at –80uC prior to analysis. The concentration of
nanoparticles added was standardized by total surface area to
deliver the same dose of CpG. For 15 nm particles, 461011
particles/ml were used, for 30 nm 1011 particles/ml were used,
and for 80 nm 1.461010 particles/ml were used.
Cytokine Concentration Measurement
The supernatants were analyzed for TNFa using an enzyme
linked immunosorbent assay (ELISA) kit (R&D Systems), following
the manufacturer’s instructions. IL-6 and G-CSF were analyzed
using a 32-plex murine cytokine/chemokine array (Millipore).
Mice and Tumor Model
C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) were
maintained in the pathogen-free mouse facility at Rice University.
This study was approved by the Institutional Animal Care and Use
Committees (IACUC) of Rice University (#A12041201). B16-
OVA tumors were formed in the flank of mice through
subcutaneous injection of 56105 cells. The length and width of
tumors were subsequently measured 3 to 4 times a week using a
digital caliper. Once the tumors reached approximately 15 mm2
in size, the CpG treatments were applied. The mice received
either intratumor injections of PBS (PBS condition), 6.4 mg CpG
1826 (Free CpG condition), or 1013 tmCpG-AuNP particles
(tmCpG-AuNP condition). The doses were repeated on days 4 and
7 after the first dose. Mice were sacrificed once the area of the
tumor reached 1 cm2, per IACUC requirements. CpG sequences
used in in vivo applications had phosphorothioate modifications to
minimize degradation.
Tumor Immune Infiltration Analysis
As with the tumor growth study, mice were implanted with
56105 B16-OVA cells in the flank. The mice received 3 injections
of PBS (n= 4), free CpG (n= 5), free tmCpG (n= 4), or tmCpG-
AuNP (n= 5) once the tumors reached an area of 15 mm2. After
24 hours, the mice were euthanized and the tumors were
harvested and passed through 70 mm cell strainers (BD Falcon).
The cells were stained with antibodies against CD8, CD4, CD11b,
CD11c, and Gr-1 (BD Biosciences) and analyzed using a BD
FACSCanto II flow cytometer.
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Statistics
All statistical analyses were done using JMP Pro Software.
Significance was assigned at the a=0.05 level. The comparisons
between the cytokine secretions caused by the different designs
and nanoparticle sizes were done using Tukey’s HSD test.
Comparisons among the conditions inducing immune cell
infiltration were also done using Tukey’s HSD test. A student’s t
test was done to calculate the differences in tumor growth.
Differences in survival were assessed using the Log Rank test.
Results
Rationale for CpG Conjugated AuNP Designs
DNA coated gold nanoparticles have been heavily studied and
often utilize self-assembling properties of the natural formation of
thiol-gold dative bonds [18,23,24]. These studies show that
modification of the functional DNA on the gold nanoparticles
can maximize its function. Therefore, we examine three different
CpG designs to extrapolate the optimal construct (Figure 1). In the
following sections, a common CpG (1826) was used (59-
TCCATGACGTTCCTGACGTT-39) for ease of comparison.
The first design is the most simple of the three. It incorporates a
thiol group modification on the 59 end of the CpG sequence
(CpG-SH), allowing CpGs to form a self-assembled monolayer
directly on the AuNP surface. The main disadvantage of this
design is that the space between the CpGs may be too small for
efficient TLR9 binding. Therefore, to improve the spacing
between the DNAs, 11 thymidine (poly-T) nucleotides are inserted
between the thiol modification and the CpG sequence (CpG-T11-
SH). This second design has been used and optimized in several
DNA-DNA or DNA-RNA binding constructs for detection or
silencing. However, for the case of CpGs, we are examining DNA-
receptor binding interactions. The rigidity of the DNA strands
may hinder the binding of the CpGs to TLR9s. Thus, for the third
design, a triethylene glycol (TEG) spacer is included between the
poly-T and the CpG sequence (CpG-TEG-T11-SH) with the
expectation that the TEG modification would allow free rotation
and further improve binding to TLR9.
Characterization of CpG Conjugated AuNP Designs
Prior to assessing the functional efficacy of the designs, the
stability and DNA content of the three CpG conjugated AuNP
constructs were evaluated using three different AuNP sizes: 15 nm,
30 nm, and 80 nm in diameter. For the different core sizes, salting
the particles during the assembling process is important for a
successful DNA coating [25]. Since AuNPs greater than 20 nm
benefit from raising the salt concentration gradually [26], the salt
concentration of the 30 nm and 80 nm CpG conjugated AuNP
constructs were increased slowly over one and a half hour, while
the 15 nm constructs were salted all at once.
The stability of the particle constructs were compared to the
citrate stabilized nanoparticles by analyzing the absorbance
spectra (Figure S1). The spectra of the DNA coated AuNP
constructs red shifted 4–5 nm for all core sizes except for the CpG-
80 nm AuNP. The CpG-80 nm AuNP aggregated and no peak
was detected. Therefore, the CpG-80 nm AuNPs were excluded
from further experiments. The shifts, however, suggests successful
conjugation of the DNA onto AuNPs. There was no broadening of
the peaks, which suggests no aggregation of these particles.
Furthermore, to determine the amount of DNA conjugated on
AuNPs of each design, the CpG strands were removed from the
particle surface through place exchange by mercaptoethanol. The
concentration of DNA in the solution was calculated by measuring
the absorbance values at 260 nm after removal of the particles
(Figure 2A). There was no significant difference of CpG content
per AuNP between the CpG-T11-SH design and the design
containing the TEG modification (CpG-TEG-T11-SH) for all
core sizes. This shows that the TEG modification did not alter the
DNA assembling process on the gold nanoparticles. Conversely,
the design with CpG-SH (132 DNA/15 nm-AuNP and 528
DNA/30 nm-AuNP) showed significantly higher loading on
AuNPs compared to the other two designs for both 15 nm and
30 nm core AuNPs (p = 0.02; p= 0.04). The CpG-T11-SH design
contained 82 DNA/15 nm-AuNP and 447 DNA/30 nm-AuNP,
and the CpG-TEG-T11-SH design contained 76 DNA/AuNP
and 445 DNA/30 nm-AuNP. These numbers are consistent with
previous reports by Demers et al. describing the surface density of
DNA on AuNPs with and without nucleotide spacers [25,27].
Functional Evaluation of CpG-AuNPs Designs in vitro
The efficacies of the different designs were evaluated by their
ability to stimulate murine macrophages to secrete tumor necrosis
factor-a (TNFa) in vitro. TNFa is a cytokine secreted by activated
macrophages and is an important component of the anti-tumor
activity of macrophages [6]. The CpG-conjugated nanoparticles
for all constructs were incubated with the macrophages overnight
Figure 1. CpG AuNP conjugate design schematics. (a) Design 1, CpG-SH, directly has CpG (black lines) assembled on the AuNP surface. (b)
Design 2, CpG-T11-SH, incorporates a poly-T nucleotide spacer (light gray lines) to increase the spacing between CpGs (straight arrows). (c) Design 3,
CpG-TEG-T11-SH, adds a triethylene glycol (dark gray dotted line) between the CpG sequence and the nucleotide spacer to allow rotation of the CpG
segment (curved arrow).
doi:10.1371/journal.pone.0063550.g001
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and the TNFa levels in the media supernatant were measured
using enzyme-linked immunosorbent assays (ELISA). The particles
concentration was standardized by overall surface area in order to
normalize the total amount of CpG delivered to the macrophages.
The CpG-TEG-T11-AuNP design, or TEG modified CpG
AuNPs, (hereby referred to as tmCpG-AuNPs) showed signifi-
cantly higher macrophage stimulation compared to the other two
designs at almost 1,400 pg/ml for 15 nm constructs (p,0.0001),
480 pg/ml for 30 nm constructs (p,0.0001), and 90 pg/ml for
80 nm constructs (p = 0.004) (Figure 2c). From these results, we
can conclude that the tmCpG design is the most effective construct
independent of core size.
It is interesting that the CpG-AuNP design (800 pg/ml) caused
higher stimulation than the CpG-T11-AuNP design (420 pg/ml)
for 15 nm constructs (p,0.0001). A similar trend was noticed by
Wei and colleagues between the CpG-T11-AuNP and CpG-AuNP
designs [28]. However, 30 nm constructs did not share the same
trend (p = 0.84). This outcome can be explained by the previous
DNA content results (Figure 2a). For the 15 nm constructs, the
CpG-AuNP design had more DNA per particle than the CpG-
T11-AuNP design. Therefore, when comparing the amount (pg) of
TNFa secreted per pmol of CpG delivered, one finds no
significant functional difference between the CpG-AuNP and
CpG-T11-AuNP designs, which also holds true for 30 nm
constructs. The tmCpG-AuNPs, however, caused significantly
higher stimulation and TNFa secretion, approximately three times
higher, compared to the other two designs (p,0.0005), again
indicating that the particles containing the TEG modification were
the most effective and displayed the highest functionality
(Figure 2c). In addition to confirming that the tmCpG was the
most effective design, the TNFa results demonstrated that
tmCpG-15 nm AuNPs were significantly better than the 30 nm
and 80 nm constructs (Figure 2B/C). However, since the
experiments prior were done separately, a combined TNFa
stimulatory experiment was performed using 15 nm, 30 nm and
80 nm tmCpG-AuNP constructs. To ensure that the 15 nm core
size supremacy was not specific to TNFa, multiplex ELISAs were
used to investigate the core size effects on other cytokines.
Furthermore, to ensure that the stimulatory effect is specific and
not caused just by the presence of DNA on the particles, control
CpG sequences were conjugated on gold nanoparticles and used
for stimulation experiments. These sequences were identical
except that the cytosine and guanine bases were in reverse order
(59-TCCATGAGCTTCCTGAGCTT-39).
The tmCpG-AuNPs of all sizes still cause significantly higher
TNFa release than the equivalent concentration of free CpG
(Figure 3a). This concentration of free CpG is the end
concentration of CpG expected based on the total amount of
CpG added to the particles during the conjugation process.
Finally, the 15 nm particles proved to be the optimal size for CpG
delivery, demonstrating significantly higher stimulation than
30 nm and 80 nm particles. A similar effect was observed when
measuring the concentration of IL-6, an inflammatory cytokine
known to be up-regulated in macrophages following CpG
stimulation [29,30] (Figure 3b). AuNP delivery also promoted
the expression of granulocyte-colony stimulating factor (G-CSF), a
Figure 2. DNA content characterization and functional TNFa assays of CpG AuNP conjugated constructs. (a) CpG AuNP conjugate
designs and DNA content of each CpG design on the 15 nm, 30 nm and 80 nm AuNPs (*p,0.05). 80 nm AuNP CpG-SH construct aggregated and
thus the DNA content was not measured. (b) TNFa levels from macrophage stimulation by CpG conjugated AuNP designs for the three particle sizes
(*p,0.05; **p,0.01). (c) TNFa levels normalized to amount of CpG presented by the nanoparticles (*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0063550.g002
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growth factor that promotes hematopoietic progenitor cell
circulation and that has been shown to be up-regulated by CpG
in vivo [31] (Figure 3c). The control sequence nanoparticles,
conversely, did not cause a significant increase in TNFa secretion
compared to untreated controls, demonstrating that there was not
non-specific stimulation caused by DNA on AuNPs.
Additionally, we assessed the effect of the three CpG sequence
designs in solution, without being conjugated to the nanoparticles,
to ensure that modifications themselves did not induce macro-
phage stimulation. None of the modifications on the CpG
sequences caused TNFa secretion. Finally, we incubated citrate
particles of all three sizes with the macrophages and found that the
particles alone did not induce TNFa secretion (Figure S2). Given
these in vitro results, the 15 nm tmCpG-AuNP design was chosen
for the following in vivo experiments.
AuNP-CpG Inhibits Tumor Growth and Promotes Survival
in mice Bearing B16-OVA tumors
C57BL/6 mice were implanted with 56105 B16-ovalbumin
(B16-OVA) tumor cells subcutaneously. Once the tumors reached
a size of ,15 mm2, we injected approximately 1013 particles into
the tumor, equivalent to a dose of about 6.4 mg CpG. We
administered the CpG treatment via intratumor injections because
this route has been shown to be superior to intravenous or
subcutaneous injections [32,33]. Subsequent doses were injected
on days 4 and 7 after the first dose, as was done in a previous
intratumor study [33]. Mice receiving equivalent doses of free
CpG or receiving injections of PBS were used as controls. Starting
on day 11 after the first dose (day 17 overall), the tmCpG-AuNP
treatment induced significant inhibition of tumor growth when
compared to free CpG (p= 0.0306) (Figure 4a). Both the free CpG
treatment and the tmCpG-AuNP treatment induced significant
tumor inhibition when compared to the PBS treatment
(p,0.0001). The difference between free CpG treatment and
AuNP treatment remained significant throughout the study
(p = 0.043 on day 19 after first injection). We also found that a
single intratumor injection of 30 nm tmCpG-AuNP significantly
inhibited tumor growth when compared to PBS treated mice
(p = 0.0124) (Figure S3).
In the control group (n= 5), the first PBS treated mouse reached
the pre-defined 1 cm2 tumor limit on day 15 of the study, and the
remainder reached the limit on day 17 (Figure 4b). In the free
CpG group (n= 10), the percentage of mice under the limit
dropped to 70% on day 25. The remaining mice reached the
tumor limit by day 39. In contrast, the percentage of mice under
the limit in the AuNP condition (n= 9) remained higher than the
free CpG condition throughout the study. Two mice (22%)
showed no measurable tumor growth after treatment and
remained under the limit until the end of the study on day 47.
Overall, the AuNP treatment promoted significantly higher
survival than the free CpG treatment (p = 0.0164).
CpG Treatment Induces Immune Cell Infiltration of the
Tumor
To elucidate the immune mechanism of tumor growth
inhibition, we analyzed the infiltration of immune cells at the
tumor site using flow cytometry. Mice were again implanted with
B16-OVA tumors and received the same 3 dose treatment
regimen of PBS (n= 4), free CpG (n= 5), free tmCpG, or
tmCpG-AuNP (n= 5) once the tumors reached a size of
approximately 15 mm2. As was done in vitro, the free tmCpG
condition was included to ensure that the modifications on the
CpG sequence were not the cause of any immune response. The
tumors were harvested 24 hours after the last treatment injection,
and the cells were then re-suspended and stained for CD8
(cytotoxic T cells), CD4 (helper T cells), CD11c (dendritic cells),
and CD11b (macrophage) expression, as well as CD11b and Gr-1
co-expression (myeloid derived suppressor cells).
Although tmCpG-AuNP treatment shows no significant differ-
ence in immune cell infiltration when compared to free CpG, it
shows significantly higher infiltration of CD11b+ (p = 0.0377),
CD11c+ (p = 0.0323), and CD11b+/Gr-1+ cells when compared to
the PBS treated condition (Figure 5). The free CpG condition
showed significantly higher infiltration of CD8+ T cells
(p = 0.0414) and CD11b+/Gr-1+ cells (p = 0.0168) when compared
to the PBS control. The free tmCpG showed no significant
infiltration of any immune cells when compared to the PBS treated
mice.
Figure 3. Cytokine and growth factor secretion following
stimulation with free CpG, AuNPs coated with control tmCpG,
or AuNPs coated with tmCpG for 15 nm, 30 nm and 80 nm core
sizes. (a) TNFa secretion, (b) IL-6 secretion, and (c) G-CSF secretion (pg/
ml) (***p,0.0001; **p,0.01; *p,0.05).
doi:10.1371/journal.pone.0063550.g003
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Discussion
The immune response following CpG treatment has been
characterized in a variety of tumor models, and a number of
immune populations have been implicated in antitumor activity.
Treatment of murine colon adenocarcinoma was shown to be
mainly mediated by CD8+ T cells with partial effect from innate
effector cells [34], while the antitumor response against large B16
melanoma tumors was dominated by macrophages [6]. Most
recently, it has been shown that CpG treatment can also inhibit
the suppressive activity of myeloid derived suppressor cells
(MDSCs), a population that inhibits T cell activity [7,8]. However,
effective CpG treatment in mice commonly requires high doses
given repeatedly, raising concerns of possible systemic toxicity
[35]. Consequently, a number of studies have focused on the use of
nanoparticles to promote delivery of CpG to APCs, thereby
enhancing its stimulatory effect. The nanoparticle formulations
explored include gelatin nanoparticles [13], liposomes [14,36],
DNA origami structures [37], and most recently, gold nanopar-
ticles [38], but these were only explored in the context of
combination treatments.
The stronger anti-tumor response of CpG bound to gold
nanoparticles compared to free oligonucleotides illustrates the
utility of gold nanoparticles for delivery of CpG and, potentially,
other immune stimulatory agents. Lee and colleagues assessed gold
nanoparticle delivery of red fluorescent protein and CpG on the
same particle in vivo and found encouraging results. However, in
their study the addition of CpG on the antigen AuNPs showed
only a modest improvement of the anti-tumor response at a single
time point. Furthermore, adding CpG on the particle had no effect
compared to antigen only particles when the mice were
immunized and then challenged with tumor cells [38]. Finally,
the effectiveness of the CpG-AuNP complexes alone was not
evaluated. We posit that the therapeutic efficacy of CpG-AuNP
particles can be improved and optimized through simple design
alterations. Here, we assessed CpG-AuNP complexes’ effectiveness
by comparing its anti-tumor effects to equivalent doses of free
CpG. We demonstrated that the oligonucleotide structure and
particle size can be designed so as to make CpG-AuNP complexes
effective for monotherapy. The design considerations discussed
here show that gold nanoparticles can be optimized for immune
stimulant delivery.
For DNA-receptor interactions, spacing between the CpG
strands can be crucial for maximum efficacy, especially since
TLR9 is an endosome membrane receptor. Using a nucleotide
Figure 4. In vivo anti-tumor effect following intratumor injections on days 0, 4, and 7, as indicated (arrows), with PBS, free CpG or
tmCpG- AuNP. (a) Tumor growth and (b) survival percentage after the first CpG injection (*p,0.05).
doi:10.1371/journal.pone.0063550.g004
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spacer reduces ‘‘steric crowding’’ of the DNA strands, thus making
the target sequence more accessible to binding [25,27]. Nucleotide
spacers have been used widely to improve functionality of DNA on
AuNPs for various applications such as antisense gene modulation
[18]. The choice of nucleotide spacer is important; poly-adenine
(poly-A) spacers yield lower nanoparticle surface coverage than
poly-thymidine (poly-T) spacers. This effect is due to adenine’s
stronger affinity to gold, which causes poly-A spacers to lie down
on the particle and restrict oligonucleotide access to the surface
[27]. Efforts to further improve binding efficacy come at a cost of
reducing the amount of DNA on the particle. Rosi et al. show that
using tetrathiol-modified DNA with nucleotide spacers further
improves the functionality of antisense oligonucleotides while
sacrificing the number of strands delivered per particle by roughly
50% [18]. Wei and colleagues used a T20/A20 duplex spacer
linked to CpGs to improve its functionality in vitro when compared
to a T20 spacer [28]; however, the use of double strand (0.11
DNA/nm2) as opposed to a single strand DNA (0.19 DNA/nm2)
reduces the surface density on gold surfaces [39] and reduces the
uptake of nanoparticles by approximately 50% [40]. Giljohann
et al. noted that higher DNA densities on AuNPs caused increased
cellular uptake [41]. Therefore, designing a CpG modified AuNP
to improve CpG functionality of the poly-T modified CpG without
sacrificing the amount of DNA per particle is critical for maximum
efficacy. We incorporated a short triethylene glycol (TEG) spacer
in between the poly-T and the CpG sequence in the tmCpG
design to address that issue. This design proved to be the most
effective, generating the highest secretion of cytokines per pmol of
CpG delivered. The large difference between efficacies of the poly-
T spacer alone CpG design versus the incorporation of TEG could
be caused by the increased rotation and mobility of the extended
CpG strand. Having free moving CpGs can improve binding to
TLR9, which is confined in the endosomal membrane.
As mentioned above, particle size can dramatically affect
particle uptake and thus affect CpG delivery and functional
efficacy. The macrophage stimulatory effect of tmCpG-AuNPs is
improved by using 15 nm particles, likely because these particles
are more easily taken up [28,42]. In addition, smaller particles
have greater curvature and thus provide more space for binding
between the DNA strands. Overall, the use of gold nanoparticles
for immune modulation is clinically valuable not only because of
the enhanced therapeutic effects, but also because of the facile
synthesis and tuning of the complex. AuNPs can be easily
functionalized and tuned to the desired size, making our design
reproducible and scalable.
The optimal 15 nm TEG modified design proved to be effective
in vivo, significantly inhibiting tumor growth and promoting
survival when compared to free CpG. Tuning of the oligonucle-
Figure 5. Percent tumor infiltration immune cells. (a) CD11b+ cells, (b) CD11c+, (c) CD8+ cells, (d) CD4+ cells, and (e) CD11b+Gr-1+ cells.
doi:10.1371/journal.pone.0063550.g005
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otide sequence and particle size permits the successful application
of CpG-AuNP complexes as a monotherapy. The ability to
enhance therapeutic activity through simple design alterations
shows that gold nanoparticles are powerful carriers and that the
design of AuNP-oligonucleotide complexes needs to be carefully
considered for optimal therapeutic effect. In this study the
significant anti-tumor activity observed in the free CpG condition
when compared to PBS controls was unexpected given the low
dose of CpG applied. However, the presence of the foreign
ovalbumin antigen is likely to promote a strong response
compared to what has been observed in other cancer models.
Nevertheless, our results indicate that conjugation to AuNP
enhances the anti-tumor effect of intratumor CpG injections. We
also observed that the free CpG treated tumors were visually
similar in shape and height (spherical) compared to the untreated
tumors, while the tmCpG-AuNP treated tumors lacked structure
or were flattened.
The tmCpG-AuNP treatment caused significantly higher
infiltration of macrophages (CD11b+ cells) and dendritic cells
(CD11c+) when compared to PBS treated mice. The treatment
showed a trend towards higher infiltration of CD8+ T cells as well,
but the finding was not significant (p = 0.0591). Interestingly, the
tmCpG-AuNP and free CpG condition caused significant
infiltration of CD11b+/Gr-1+ myeloid derived suppressor cells
(MDSCs), an immune suppressive population that is known to
promote tumor growth. However, as aforementioned, CpG
treatment has been shown to reduce the suppressive activity of
MDSCs. Therefore, even though the inflammatory response
induced by CpG may attract infiltration of MDSCs, the treatment
may be inhibiting the immune suppressive activity of these cells.
For instance, Zoglmeier et al. report that CpG treatment does not
reduce the percentage of splenic MDSCs in tumor bearing mice
but does inhibit their ability to suppress T cell proliferation [8].
Future studies isolating tumor and splenic MDSCs following free
CpG and tmCpG-AuNP injections can elucidate whether the
treatments used here can inhibit MDSC activity.
Overall, the anti-tumor activity of the tmCpG-AuNP treatment
appears to be mediated by the significant infiltration of macro-
phages and dendritic cells to the tumor site. We did not observe
significant differences in infiltration between the free CpG and the
tmCpG-AuNP conditions and thus cannot ascertain the immu-
nological differences that may have made the tmCpG-AuNP
treatment more effective in vivo. The increased efficacy of the
tmCpG-AuNP may result from its effect on immune suppressive
populations such as MDSCs or regulatory T cells; characterizing
whether AuNPs can enhance the inhibitory effect that CpG has on
MDSC activity merits further work.
In conclusion, CpG oligonucleotides are immune stimulatory
agents that have shown clinical promise as single treatments and as
vaccine adjuvants [4,5]. However, CpG treatment can be limited
by the need for high doses and by non-specific toxicity [35], such
as systemic cytokine increase and coagulation inhibition [5].
Nanotechnology can address such concerns by enhancing delivery
of CpG to antigen presenting cells, and a number of nanocarriers
have been explored for this purpose [13,14,36–38]. Here we show
that gold nanoparticles are an effective CpG carrier, enhancing
the effect of CpG treatment both in vitro and in vivo. We developed
a new design utilizing a poly-T and TEG spacer that enhances
CpG functionality without lowering DNA content on the gold
nanoparticle. In addition, we demonstrate that a monotherapy of
AuNP-delivered CpG can inhibit tumor growth and promote
survival when compared to the equivalent dose of free CpG.
Future studies will explore AuNP delivered CpG in combination
treatments and in metastatic disease models.
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The supporting information includes absorbance data on the
particles, in vivo data for 30 nm tmCpG-AuNP particles, and
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